Scarica l'app Stockscreener
3.99
0.25%
-0.010
Dopo l'orario di chiusura:
3.90
-0.09
-2.26%
Precedente Chiudi:
$4.00
Aprire:
$4
Volume 24 ore:
24,382
Relative Volume:
0.09
Capitalizzazione di mercato:
$2.32M
Reddito:
$644.60K
Utile/perdita netta:
$-9.87M
Rapporto P/E:
-0.00476
EPS:
-837.9618
Flusso di cassa netto:
$-9.02M
1 W Prestazione:
-5.00%
1M Prestazione:
+3.64%
6M Prestazione:
-83.88%
1 anno Prestazione:
-93.86%
Intervallo 1D:
$3.90
$4.2151
Intervallo di 1 settimana:
$3.80
$4.3912
Portata 52W:
$3.50
$74.00
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Nome
Biodexa Pharmaceuticals Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta BDRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
3.99 | 2.32M | 644.60K | -9.87M | -9.02M | -837.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-08 | Iniziato | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr Borsa (BDRX) Ultime notizie
Biodexa Pharmaceuticals Plc ADR (BDRX): A New Perspective - Stocks Register
Result of General Meeting - Yahoo Finance
Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic - Barchart
Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com
Notice of General Meeting - StockTitan
Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod - TipRanks
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Biodexa reports promising glioblastoma trial results - Investing.com
Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 study - TipRanks
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - StockTitan
Stock Surge: Biodexa Pharmaceuticals Plc ADR (BDRX) Closes at 5.01, Marking a -4.21 Increase/Decrease - The Dwinnex
Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension - TipRanks
Biodexa secures Nasdaq listing extension - Investing.com
Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - TipRanks
Biodexa secures Nasdaq listing extension By Investing.com - Investing.com UK
Biodexa Announces Successful Appeal of Nasdaq Delisting - StockTitan
Biodexa provides update on PFS, OS in Phase 1 study of MTX110 in rGBM - TipRanks
Biodexa reports survival rates in glioblastoma study - Investing.com India
Biodexa reports updated Phase 1 data from glioblastoma study (NASDAQ:BDRX) - Seeking Alpha
Biodexa’s MTX110 Shows Promise in Brain Cancer Study - TipRanks
Biodexa reports survival rates in glioblastoma study By Investing.com - Investing.com UK
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - StockTitan
Ratio Analysis: Unpacking Biodexa Pharmaceuticals Plc ADR (BDRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: A Year of Declines and Increases - The InvestChronicle
Should investors be concerned about BDRX’s high price-to-sales ratio? - US Post News
Interim results for the six months ended June 30, 2024 - StockTitan
Market Watch Highlights: Biodexa Pharmaceuticals Plc ADR (BDRX) Ends on an Downturn Note at 0.29 - The Dwinnex
Biodexa Pharmaceuticals announces ADR ratio change - Investing.com
ADR Ratio Change - Markets Insider
Biodexa Pharmaceuticals Announces ADR Ratio Change - TipRanks
Biodexa secures full access to cancer research grant - Investing.com
BDRX Stock on the Rise: A Promising Investment - The InvestChronicle
Financial Health Report: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Ratios Tell a Tale - The Dwinnex
Biodexa Pharmaceuticals Plc ADR (BDRX) produces promising results - US Post News
Investors in cash trouble should check out Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News
Receipt of Nasdaq Delisting DeterminationPlans to Appeal - StockTitan
Biodexa Pharmaceuticals Plc ADR (BDRX) is a good investment, but the stock may be undervalued - US Post News
Balance Sheet Breakdown: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Biodexa Pharmaceuticals sets $5 million offering - Investing.com
Financial Metrics Check: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Ratios for Trailing Twelve Months - The Dwinnex
BDRX Stock Price and Chart — NASDAQ:BDRX - TradingView
Are Smart Investors Making the Right Decision? Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News
Biodexa’s Diabetes Drug Enters Phase 2a Studies - TipRanks
The time has not yet come to remove your chips from the table: Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News
Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Benzinga
eRapa shows promise in Phase 2 for FAP treatment, Biodexa reveals - Investing.com
BDRX’s Stock Market Adventure: -73.47% YTD Growth Amidst Volatility - The InvestChronicle
Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI TractNow 12-Month Data - StockTitan
Midatech Pharma PLC Announces Posting of Annual Report & Notice of AGM - Quantisnow
Midatech Pharma PLC Announces Business Update - Quantisnow
Biodexa Pharmaceuticals Plc Adr Azioni (BDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):